News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Acorda Therapeutics MS Walking Drug Sales Shine; Loss Narrows
August 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK Aug 3 (Reuters) - Acorda Therapeutics Inc (ACOR.O) reported second-quarter sales that were double Wall Street expectations for its new Ampyra drug to improve walking in multiple sclerosis patients.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Neuroscience
Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy
September 8, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
AC Immune To Cut 30% of Workforce
September 5, 2025
·
196 min read
·
BioSpace Editorial Staff
China
Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+
September 5, 2025
·
2 min read
·
Tristan Manalac
Layoffs
AC Immune Downsizes by 30%, Narrows Pipeline Focus
September 4, 2025
·
2 min read
·
Tristan Manalac
